Lipid nanocapsule functionalization by lipopeptides derived from human papillomavirus type-16 capsid for nucleic acid delivery into cancer cells

International Journal of Pharmaceutics

Volumn 454, Issue 2, 2013, Pages 756-764

  Weyland, M ^a,b   Griveau, A ^a,b   Bejaud, J ^a,b   Benoit, J P ^a,b   Coursaget, P ^c   Garcion, E ^a,b  

^a UNIVERSITÉ D'ANGERS   (France)

^b LUNAM Universite   (France)

^c UNIVERSITÉ DE TOURS   (France)

Author keywords

Cancer; DNA; Nanoparticles; Papillomavirus derived peptide; siRNA; Vectorization

Indexed keywords

HEPARAN SULFATE; LIPID; LIPOPEPTIDE; NANOCAPSULE; PLASMID DNA; SMALL INTERFERING RNA;

ARTICLE; BIOMIMETICS; CANCER CELL CULTURE; CELL STRAIN CACO 2; CELL SURFACE; CELLULAR DISTRIBUTION; COLORECTAL CARCINOMA; COMPLEX FORMATION; EXTRACELLULAR MATRIX; GENETIC TRANSFECTION; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; INTERNALIZATION; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUCLEIC ACID TRANSPORT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REACTION TIME; VIRUS CAPSID; ZETA POTENTIAL;

CANCER; DNA; NANOPARTICLES; PAPILLOMAVIRUS DERIVED PEPTIDE; SIRNA; VECTORIZATION;

ANIMALS; ANTIGENS, CD; CAPSID PROTEINS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; DNA; GLYCOPROTEINS; HUMANS; LIPIDS; LIPOPEPTIDES; NANOCAPSULES; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PEPTIDES; PLASMIDS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING;

EID: 84884169121     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.06.013     Document Type: Article

References (38)

1. Beduneau, A., Hindre, F., Clavreul, A., Leroux, J.C., Saulnier, P., Benoit, J.P., 2008. Brain targeting using novel lipid nanovectors. J. Control Release 126, 44-49. (Pubitemid 351175685)
2. Bousarghin, L., Touze, A., Combita-Rojas, A.L., Coursaget P, 2003a. Positively charged sequences of human papillomavirus type 16 capsid proteins are sufficient to mediate gene transfer into target cells via the heparan sulfate receptor. J. Gen. Virol. 84, 157-164. (Pubitemid 36113561)
3. Bousarghin, L., Touze, A., Sizaret, P.Y., Coursaget P, 2003b. Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells. J. Virol. 77, 3846-3850. (Pubitemid 36297304)
4. Bousarghin, L., Touze, A., Yvonnet, B., Coursaget, P., 2004. Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity. J. Med. Virol. 73, 474-480. (Pubitemid 38685756)
5. Bousarghin, L., Touze, A., Gaud, G., Iochmann, S., Alvarez, E., Reverdiau, P., Gaitan, J., Jourdan, M.L., Sizaret, P.Y., Coursaget, P.L., 2009. Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol. Cancer Ther. 8, 357-365.
6. Chang, J., Paillard, A., Passirani, C., Morille, M., Benoit, J.P., Betbeder, D., Garcion, E., 2012. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm. Res. 29, 1495-1505.
7. Cho, Y.W., Kim, J.D., Park, K., 2003. Polycation gene delivery systems: escape from endosomes to cytosol. J. Pharm. Pharmacol. 55, 721-734. (Pubitemid 36752715)
8. Combelas, N., Saussereau, E., Fleury, M.J., Ribeiro, T., Gaitan, J., Duarte-Forero, D.F., Coursaget, P., Touze, A., 2010. Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies. J. Transl. Med. 8, 28.
9. Davis, M.E., Zuckerman, J.E., Choi, C.H., Seligson, D., Tolcher, A., Alabi, C.A., Yen, Y., Heidel, J.D., Ribas, A., 2010. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070.
10. Derossi, D., Joliot, A.H., Chassaing, G., Prochiantz, A., 1994. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269, 10444-10450. (Pubitemid 24198241)
11. El Ouahabi, A., Thiry, M., Pector, V., Fuks, R., Ruysschaert, J.M., Vandenbranden, M., 1997. The role of endosome destabilizing activity in the gene transfer process mediated by cationic lipids. FEBS Lett. 414, 187-192. (Pubitemid 27389360)
12. Elbashir, S.M., Lendeckel, W., Tuschl, T., 2001. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15, 188-200. (Pubitemid 32107664)
13. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., Mello, C.C., 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811. (Pubitemid 28099681)
14. Garcion, E., Lamprecht, A., Heurtault, B., Paillard, A., Aubert-Pouessel, A., Denizot, B., Menei, P., Benoit, J.P., 2006. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol. Cancer Ther. 5, 1710-1722. (Pubitemid 44323239)
15. Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., Asnafi, V., MacIntyre, E., Dal Cortivo, L., Radford, I., Brousse, N., Sigaux, F., Moshous, D., Hauer, J., Borkhardt, A., Belohradsky, B.H., Wintergerst, U., Velez, M.C., Leiva, L., Sorensen, R., Wulffraat, N., Blanche, S., Bushman, F.D., Fischer, A., Cavazzana-Calvo, M., 2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142.
16. Kawabata, K., Takakura, Y., Hashida, M., 1995. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm. Res. 12, 825-830.
17. Khalil, I.A., Kogure, K., Akita, H., Harashima, H., 2006. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol. Rev. 58, 32-45.
18. Kim, S.K., Huang, L., 2012. Nanoparticle delivery of a peptide targeting EGFR signaling. J. Control Release 157, 279-286.
19. Lacoeuille, F., Garcion, E., Benoit, J.P., Lamprecht, A., 2007. Lipid nanocapsules for intracellular drug delivery of anticancer drugs. J. Nanosci. Nanotechnol. 7, 4612-4617.
20. Lam, J.K., Liang, W., Chan, H.K., 2012. Pulmonary delivery of therapeutic siRNA. Adv. Drug Deliv. Rev. 64, 1-15.
21. Liu, M.A., 2011. DNA vaccines: an historical perspective and view to the future. Immunol. Rev. 239, 62-84.
22. Ma, Y., Nolte, R.J., Cornelissen, J.J., 2012. Virus-based nanocarriers for drug delivery. Adv. Drug Deliv. Rev. 64, 811-825.
23. Ortiz, M.E., Endy, D., 2012. Engineered cell-cell communication via DNA messaging. J. Biol. Eng. 6, 16.
24. Paillard, A., Hindre, F., Vignes-Colombeix, C., Benoit, J.P., Garcion, E., 2010. The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials 31, 7542-7554.
25. Pearce, T.R., Shroff, K., Kokkoli, E., 2012. Peptide targeted lipid nanoparticles for anticancer drug delivery. Adv. Mater. 24, 3803-3822, 3710.
26. Peer, D., Karp, J.M., Hong, S., Farokhzad, O.C., Margalit, R., Langer, R., 2007. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760. (Pubitemid 350223348)
27. Perez-Martinez, F.C., Guerra, J., Posadas, I., Cena, V., 2011. Barriers to non-viral vector-mediated gene delivery in the nervous system. Pharm. Res. 28, 1843-1858.
28. Platet, N., Liu, S.Y., Atifi, M.E., Oliver, L., Vallette, F.M., Berger, F., Wion, D., 2007. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett. 258, 286-290. (Pubitemid 350110377)
29. Poillot, C., De Waard, M., 2011. Potential of cell penetrating peptides for cell drug delivery. Med. Sci. (Paris) 27, 527-534.
30. Roger, E., Lagarce, F., Garcion, E., Benoit, J.P., 2010. Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells. Eur. J. Pharm. Sci. 40, 422-429.
31. Ruoslahti, E., 2012. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv. Mater. 24, 3747-3756.
32. Salvati, A., Pitek, A.S., Monopoli, M.P., Prapainop, K., Bombelli, F.B., Hristov, D.R., Kelly, P.M., Aberg, C., Mahon, E., Dawson, K.A., 2013. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 8, 137-143.
33. Su, W., Wang, H., Wang, S., Liao, Z., Kang, S., Peng, Y., Han, L., Chang, J., 2012. PEG/RGD-modified magnetic polymeric liposomes for controlled drug release and tumor cell targeting. Int. J. Pharm. 426, 170-181.
34. Torchilin, V., 2009. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur. J. Pharm. Biopharm. 71, 431-444.
35. Vanpouille-Box, C., Lacoeuille, F., Belloche, C., Lepareur, N., Lemaire, L., LeJeune, J.J., Benoit, J.P., Menei, P., Couturier, O.F., Garcion, E., Hindre, F., 2011. Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)Re-lipid nanocapsules. Biomaterials 32, 6781-6790.
36. Weyland, M., Manero, F., Paillard, A., Gree, D., Viault, G., Jarnet, D., Menei, P., Juin, P., Chourpa, I., Benoit, J.P., Gree, R., Garcion, E., 2011. Mitochondrial targeting by use of lipid nanocapsules loaded with SV30, an analogue of the small-molecule Bcl-2 inhibitor HA14-1. J. Control Release 151, 74-82.
37. Wianny, F., Zernicka-Goetz, M., 2000. Specific interference with gene function by double-stranded RNA in early mouse development. Nat. Cell. Biol. 2, 70-75.
38. Zhang, Y., Wang, C.W., Wang, Z.G., Ma, D.X., Pan, S., Zhu, S.G., Li, F., Wang, B., 2008. Construction of double suicide genes system controlled by MDR1 promoter with targeted expression in drug-resistant glioma cells. J. Neurooncol. 86, 3-11. (Pubitemid 350263427)